Key Takeaways Bristol Myers launched a restructuring program to counter sales hit from generic competition.The program is set to cost $2.5B through 2027, with$1.4B already incurred.BMY expects $2B in annual savings by 2027, supporting a leaner operating model.Bristol Myers ((BMY) is looking to boost its bottom-line growth as generic competition for legacy drugs (Revlimid, Pomalyst, Sprycel, and Abraxane) pulls down the top line. In 2023, BMY initiated a restructuring program to streamline its operating mod ...